Expanding Global Footprint Sequent Scientific has established manufacturing facilities across Europe, Turkey, Brazil, and India, including a USFDA-approved veterinary API site in Vizag. This broad geographic presence offers opportunities to introduce new products tailored to regional markets and leverage regional distribution channels.

Strong Industry Position As India’s largest animal health company and among the top 20 globally, Sequent Scientific is well-positioned to expand its market share through strategic partnerships, joint ventures, or new product development in the rapidly growing animal health sector.

Innovation and Product Launches Sequent demonstrated innovation with the launch of Halofusol for veterinary use across 19 European countries. Introducing new, differentiated formulations presents a sales opportunity to target veterinary clinics, pharmacies, and distributors worldwide.

Financial Growth Potential With revenues between 25 and 50 million dollars and recent funding of 17 million dollars, the company has the capacity to invest in expanding product lines, acquiring smaller competitors, or increasing marketing efforts to accelerate growth.

Leadership and Strategic Changes Recent leadership appointments and managerial transitions suggest a company in evolution, open to forming new collaborations or expanding existing partnerships, which could be advantageous for sales teams seeking fresh opportunities and tailored solutions.